Lantheus has completed its acquisition of Life Molecular Imaging Ltd. Please see the press release to learn more.
Lantheus has completed its acquisition of Life Molecular Imaging Ltd. Please see the press release to learn more.
Molecular imaging provides unique insights into the human body, enabling physicians to provide an improved diagnosis and personalize patient care
Molecular imaging provides unique insights into the human body, enabling physicians to provide an improved diagnosis and personalize patient care
Our mission is to develop novel PET tracers in the field of molecular imaging that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.
Life Molecular Imaging, a Lantheus Company, is developing a product portfolio of innovative molecular imaging tracers that address major clinical needs in neurology and cardiology.
Our lead product is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.
